Qure Ventures
Qure Ventures is venture capital firm under OurCrowd. Qure is led by successful digital health veterans with vast experience founding, growing, and exiting companies over the last 20+ years. Qure has established strategic partnerships with key stakeholders in consumer, provider, payer, as well as pharma domains - providing fast track access to market and clinical trial opportunities for portfolio companies. Qure is Israel's first exclusively focused digital health fund. The fund focuses predominantly on startups located in Israel, home to world's leading tech + digital health ecosystem. OurCrowd's global network, investment leadership and in-house medical expertise provide Qure with unparalleled deal access and robust diligence.
CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.
CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.